Merck Dirección

Dirección controles de criterios 3/4

El CEO de Merck's es Rob Davis , nombrado en Apr 2021, tiene una permanencia de 2.75 años. compensación anual total es $20.27M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.014% de las acciones de la empresa, por valor de ARS39.78B. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 5.6 años, respectivamente.

Información clave

Rob Davis

Chief Executive Officer (CEO)

US$20.3m

Compensación total

Porcentaje del salario del CEO	7.9%
Permanencia del CEO	3.1yrs
Participación del CEO	0.01%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rob Davis en comparación con los beneficios de Merck?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

Compensación vs. Mercado: La compensación total de Rob($USD20.27M) está por encima de la media de empresas de tamaño similar en el mercado AR ($USD6.04M).

Compensación vs. Ingresos: La compensación de Rob ha sido consistente con los resultados de la empresa en el último año.

CEO

Rob Davis (56 yo)

3.1yrs

Permanencia

US$20,273,287

Compensación

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Davis	Chairman	3.1yrs	US$20.27m	0.014% $ 39.4b
Caroline Litchfield	Executive VP & CFO	3.1yrs	US$8.30m	0.0020% $ 5.8b
Richard DeLuca	Executive VP & President of Merck Animal Health	12.7yrs	US$6.20m	0.0054% $ 15.5b
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	14.5yrs	US$6.24m	0.0062% $ 17.8b
Dean Li	Executive VP & President of Merck Research Laboratories	6.5yrs	US$9.78m	0.0018% $ 5.2b
Dalton Smart	Senior VP of Finance	less than a year	sin datos	0.00011% $ 315.3m
David Williams	Executive VP and Chief Information & Digital Officer	no data	sin datos	0.00078% $ 2.2b
Peter Dannenbaum	Vice President of Investor Relations	4.8yrs	sin datos	sin datos
Jennifer Zachary	Executive VP & General Counsel	6.1yrs	US$5.90m	0.0011% $ 3.3b
Lisa LeCointe-Cephas	Senior VP and Chief Ethics & Compliance Officer	3.1yrs	sin datos	0.00020% $ 573.3m
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	2.8yrs	sin datos	sin datos
Betty Larson	Executive VP & Chief Human Resources Officer	less than a year	sin datos	sin datos

3.1yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MRK se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Davis	Chairman	2.8yrs	US$20.27m	0.014% $ 39.4b
Peter Wendell	Independent Director	20.7yrs	US$370.00k	0.000040% $ 114.7m
Pamela Craig	Independent Director	8.7yrs	US$400.00k	0.000070% $ 200.7m
Patricia Russo	Independent Director	28.7yrs	US$360.00k	0.00052% $ 1.5b
Thomas Glocer	Independent Lead Director	16.5yrs	US$430.10k	0.00020% $ 573.3m
Risa Lavizzo-Mourey	Independent Director	4yrs	US$365.00k	0.000040% $ 114.7m
Inge Thulin	Independent Director	6.2yrs	US$340.00k	0% $ 0
Stephen Mayo	Independent Director	3.2yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	4.2yrs	US$350.00k	0.000020% $ 57.3m
Christine Seidman	Independent Director	4.2yrs	US$350.00k	0% $ 0
Paul Rothman	Independent Director	8.7yrs	US$380.00k	0% $ 0
Mary Coe	Independent Director	5.2yrs	US$350.00k	0% $ 0

5.7yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de MRK se considera experimentada (5.6 años de antigüedad promedio).

Merck Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Merck & Co., Inc., Annual General Meeting, May 28, 2024

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Recent updates

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Merck & Co., Inc. (NYSE:MRK) entered into definitive agreement to acquire an unknown stake in Caraway Therapeutics, Inc. from AbbVie Ventures, Inc., SV Health Investors, LLC,Dementia Discovery LP, Amgen Ventures and Eisai Innovation Inc. for $610 million.

FDA Approves Merck’s KEYTRUDA (Pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad